Welcome to our dedicated page for ADC Therapeutics SA SEC filings (Ticker: ADCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
ADC Therapeutics SA filings document the regulatory record of a Swiss commercial-stage biotechnology company with common shares listed on the New York Stock Exchange. Its Form 8-K reports cover operating results, preliminary financial information, Regulation FD presentations, clinical data updates for ZYNLONTA studies, and material agreements including amendments to royalty financing arrangements.
Proxy materials describe annual general meeting matters under Swiss law, including approval of annual and consolidated financial statements, compensation report votes, discharge of directors and executive committee members, board and compensation committee elections, auditor matters and share capital governance. The filings also identify the company’s registered common shares, par value and exchange listing.
ADC Therapeutics SA is reported to have a significant shareholder group led by Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack. As of June 30, 2026, they may be deemed to beneficially own 12,326,184 common shares of ADC Therapeutics, representing 9.69% of the outstanding common shares.
All reported holdings are held through funds and separately managed accounts controlled by Nantahala. The Reporting Persons have no sole voting or dispositive power over the shares; instead, they report shared voting and shared dispositive power over the full 12,326,184 shares.
ADC Therapeutics reported second-quarter 2026 net revenue of $19.2 million, up slightly from 2025, driven by higher U.S. ZYNLONTA pricing, while six‑month revenue was $40.1 million, modestly below the prior year due to lower license and milestone income. The company narrowed its net loss to $16.6 million for the quarter and $49.5 million for the first half, helped by sharply lower R&D spending after its 2025 restructuring and a non‑cash gain from revaluing HCR warrants.
Cash and cash equivalents were $219.1 million at June 30, 2026, with six‑month operating cash outflow of $41.5 million. The balance sheet shows negative shareholders’ equity of $228.2 million, reflecting an accumulated deficit of $1.69 billion, a $320.6 million deferred royalty obligation, and $116.6 million of senior secured term loans.
Clinically, ZYNLONTA plus rituximab met the primary endpoint of progression‑free survival in the Phase 3 LOTIS‑5 trial (HR 0.73; p=0.008), but the FDA expressed substantial concerns about benefit‑risk in light of higher Grade 5 events and a marginal efficacy benefit. ADC is reassessing its regulatory strategy while continuing monotherapy commercialization under accelerated approval. The LOTIS‑7 Phase 1b glofitamab combination completed enrollment with previously reported high response rates, and the company plans a Breakthrough Therapy designation request. A new 2026 restructuring will reduce the remaining global workforce by about 17% to focus resources on ZYNLONTA.
ADC Therapeutics reported second-quarter 2026 net product revenue of $18.6 million, roughly flat year over year, and total revenue of $19.2 million. Aggressive cost control cut total operating expenses to $44.7 million, down 29% from 2025, reducing the quarterly net loss to $16.6 million from $56.6 million. Adjusted operating expenses fell 22% to $37.2 million, and adjusted net loss narrowed to $16.3 million.
Cash and cash equivalents were $219.1 million at June 30, 2026, with the company stating an expected cash runway at least into 2028. A June 2026 reorganization, including a 17% workforce reduction, is expected to generate about $10 million in annualized savings.
On the clinical side, the Phase 3 LOTIS-5 trial of ZYNLONTA plus rituximab met its primary PFS endpoint, but the FDA expressed substantial concerns about benefit–risk given an imbalance in Grade 5 events and marginal treatment benefit, leaving the full-approval path under evaluation. The LOTIS-7 Phase 1b trial of ZYNLONTA plus glofitamab completed enrollment and shows high complete response rates in relapsed/refractory DLBCL, with plans to seek Breakthrough Therapy designation and explore a Phase 3 program. Investigator-initiated trials in marginal zone and follicular lymphomas report high complete response rates and durable disease control, supporting potential compendia and regulatory strategies from 2027 onward.
BlackRock, Inc. reports a significant ownership position in ADC Therapeutics SA common stock. BlackRock and certain of its business units beneficially own 6,857,815 shares of ADC Therapeutics, representing 5.4% of the outstanding common stock.
BlackRock has sole voting power over 6,765,332 shares and sole dispositive power over all 6,857,815 shares, with no shared voting or dispositive power reported. Various underlying clients and investors have the right to receive dividends and sale proceeds from these shares, but no single such person holds more than five percent of ADC Therapeutics’ total outstanding common shares. The filing is signed by Managing Director Spencer Fleming on behalf of BlackRock.
Zaki Mohamed reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA Chief Medical Officer Zaki Mohamed received an equity award in the form of restricted stock units. On June 30, 2026 he was granted 213,900 RSUs, each representing the right to receive one common share at no purchase price.
The RSUs will vest on the earlier of June 30, 2027 or a qualifying termination without cause or for good reason, provided he remains employed through the vesting date. Following this grant, Mohamed holds 896,317 common shares directly, highlighting that this is a compensation-related award rather than an open-market share purchase or sale.
GRAHAM PETER J reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics disclosed that Chief Legal Officer Peter J. Graham received an award of 221,100 restricted stock units (RSUs) of common shares on June 30, 2026 under an incentive award letter agreement. The RSUs vest on the earlier of June 30, 2027 or certain termination events, subject to continued employment. Each RSU represents a right to receive one common share, bringing his direct holdings to 841,640 common shares after the award.
ADC Therapeutics reported that its Chief Financial Officer, Jose Carmona, received an award of 203,700 restricted stock units on June 30, 2026. These RSUs vest on the earlier of June 30, 2027 or certain qualifying termination events, assuming continued employment. Each RSU converts into one common share, bringing his direct holdings to 938,076 common shares after the award.
MALLIK AMEET reported acquisition or exercise transactions in this Form 4 filing.
ADC Therapeutics SA reported that Chief Executive Officer Ameet Mallik received an equity compensation award in the form of 675,000 restricted stock units on June 30, 2026. These RSUs vest upon the earlier of June 30, 2027 or certain qualifying terminations of employment, conditioned on continued service. Following the grant, Mallik directly holds 2,121,769 common shares.
ADC Therapeutics approved one-time retention awards for key executives to encourage them to stay with the company. On June 30, 2026, the board, advised by its independent compensation consultant, granted cash bonuses payable on or about July 15, 2026 and restricted stock units (RSUs) that vest after one year or upon certain terminations.
CEO Ameet Mallik will receive a cash incentive of $1,795,500 and 675,000 RSUs, CFO Jose Carmona will receive $541,842 and 203,700 RSUs, and Chief Medical Officer Mohamed Zaki will receive $568,974 and 213,900 RSUs. Executives must generally remain employed through June 30, 2027 to keep the cash awards and for RSUs to vest, except if they are terminated without cause or resign for good reason.
ADC Therapeutics is implementing a strategic reorganization centered on its ZYNLONTA franchise, including a global workforce reduction of approximately 17 percent. This move is tied to the expected completion of the LOTIS-5 and LOTIS-7 trials and to operational efficiencies.
The company expects the reorganization to generate annualized estimated cost savings of about $10 million, while incurring one-time pre-tax charges of roughly $3 million for severance, benefits and related termination costs, mostly in the second quarter of 2026. Management states it has an expected cash runway at least into 2028 and is preparing for an August 2026 pre-sBLA meeting with the FDA for LOTIS-5, with an sBLA submission planned for the fourth quarter of 2026 and full LOTIS-7 data anticipated by the end of 2026.